Lipid nanoparticles (LNPs) are the leading clinical delivery system for small interfering RNA (siRNA), yet after endocytosis roughly 70% of the internalized siRNA is exported back out of the cell through recycling of LNPs from late endosomes/lysosomes, and only a small fraction reaches the cytosolic RNA-induced silencing complex (RISC). The source study (Sahay et al., 2013) showed that genetic loss of the late-endosomal cholesterol transporter Niemann-Pick C1 (NPC1) or depletion of the Rab GTPase Rab27b traps LNPs in enlarged late endosomes/lysosomes and increases functional gene silencing, but left the mechanism unresolved. In the subsequent literature, the retention strategy was pharmacologically validated only in vitro (2016) and shown to be carrier-dependent; the compartment and mechanism of endosomal escape remain openly contested through 2026; in-vivo quantification of escape and its trafficking determinants only became feasible in 2026; and the questions of safe therapeutic exploitation, and of delivery in lysosomal storage diseases, remain untouched. The problem — establish whether and how prolonged late-endosomal residence is converted into functional cytosolic RISC delivery, and whether that conversion can be safely harnessed in vivo — remains open.

Background

RNA interference (RNAi) is a natural process in which short double-stranded RNAs, called small interfering RNAs (siRNAs), are loaded into a multi-protein complex, the RNA-induced silencing complex (RISC), which uses one strand as a guide to find complementary messenger RNAs and direct their destruction, thereby silencing the target gene. Because RISC acts in the cytosol, siRNA drugs must cross cell membranes to work. The most advanced delivery vehicle is the lipid nanoparticle (LNP), a roughly 50-100 nm particle made of ionizable (charge-shifting) lipids, helper phospholipids, cholesterol and PEG-lipids that encapsulates siRNA; the first approved RNAi medicine, patisiran (2018), delivers siRNA to liver cells in LNPs. LNPs enter cells by endocytosis — for the cationic LNPs studied in the source paper, mainly macropinocytosis, an actin-driven engulfment of surrounding fluid — and land in membrane-bounded endosomes, which mature into acidic late endosomes and then degradative lysosomes. For siRNA to function, it must leave this endosomal system ('endosomal escape') before the particle is degraded in lysosomes or shipped back out of the cell. Late endosomes, also called multivesicular bodies (MVBs), bud small intraluminal vesicles into their lumen and can fuse either with lysosomes or with the plasma membrane, releasing their intraluminal vesicles as exosomes. NPC1 is a late-endosomal/lysosomal membrane protein that exports cholesterol out of these compartments; its loss causes Niemann-Pick type C disease, a lysosomal storage disorder in which cholesterol-engorged late endosomes/lysosomes accumulate. Rab proteins are small GTPases that specify vesicular trafficking routes: for example Rab27b controls secretory lysosome and exosome release, and Rab7 controls late-endosome maturation.

The source paper (Sahay et al., Nature Biotechnology, 2013) combined automated high-throughput confocal imaging with systematic perturbation of cellular pathways to follow the intracellular fate of LNP-delivered siRNA. It found that endocytosed LNP-siRNA is largely lost to exocytosis: about 70% of internalized siRNA leaves the cell again as intact LNPs exit late endosomes/lysosomes through recycling routes that require NPC1. In NPC1-deficient cells (a model of Niemann-Pick type C) and after depletion of Rab27b, LNPs are retained in enlarged, perinuclear late endosomes/lysosomes, and gene silencing is substantially enhanced. Contemporaneous quantitative imaging studies of comparable systems showed how rare productive delivery is: only about 1-2% of internalized siRNA escapes to the cytosol, during a limited time window, from a compartment with mixed early and late endosomal character (Gilleron et al., 2013), and release appears to occur from maturing endosomes within minutes of uptake, with cytosolic galectin proteins immediately tagging the damaged endosomes for autophagy (Wittrup et al., 2015).

These observations define a well-posed but unanswered mechanistic puzzle. Blocking recycling clearly increases retention and functional knockdown, yet retention per se does not explain how siRNA crosses the endosomal limiting membrane into the cytosol. The source paper proposed, as hypotheses only, that the increased residence time of more siRNA inside cells results in slow controlled diffusion of the siRNA across the limiting membrane into the cytoplasm, or that LNPs remain stalled in a manner that affects siRNA delivery to membrane-associated RISC (RISC components had been reported on late-endosomal membranes and inside intraluminal vesicles by Gibbings et al., 2009). It also pointed to future studies targeting the proteins and lipids involved in biogenesis, trafficking and recycling of the late endosomes as a source of further clues about the cellular factors that may improve drug delivery, speculated that LNPs may demonstrate enhanced siRNA/drug delivery in lysosomal storage diseases where NPC1 function is impaired, and suggested that siRNA delivery efficiency might be improved by designing delivery vehicles that can escape the recycling pathways. Two further concerns are not raised in the source paper: the generalization of the NPC1 and Rab27b effects across LNP chemistries and in vivo, and the safety of deliberately inhibiting recycling (which, if chronic, mimics Niemann-Pick-type lipid trafficking disruption).

Problem Statement

Determine, with mechanistic and causal resolution, whether and how prolonged residence of LNP-delivered siRNA in late endosomes/lysosomes is converted into functional cytosolic RISC delivery, and whether and how this conversion can be deliberately increased — safely and in vivo — by blocking endocytic recycling. The common scientific objective uniting the following linked questions is to explain the observed enhancement of gene silencing when late-endosomal recycling is blocked, and to establish its exploitable scope. Questions (1), (2) and (4) are raised in the discussion of Sahay et al. 2013; question (3) extends that paper's suggestion that siRNA delivery efficiency might be improved by designing delivery vehicles that can escape the recycling pathways. Each of (1)-(4) is an independently reportable sub-question with its own completion boundary — (1) is resolved by establishing the causal mechanism that converts late-endosomal residence into functional cytosolic RISC delivery, (2) by identifying the molecular determinants of LNP routing, (3) by establishing the in-vivo breadth of the NPC1/Rab27b effect and the safety of transient recycling inhibition, and (4) by the disease-state consequence — so a partial answer resolves only the sub-question it addresses; the overall objective is met when the mechanism (1) and its exploitable scope (2)-(4) are jointly established.

(1) Mechanism of the residence-to-delivery conversion: determine whether the increased retention of LNP-delivered siRNA in enlarged late endosomes/lysosomes (as in NPC1-deficient or Rab27b-depleted cells) is causal for functional delivery to cytosolic RISC and, if it is, identify the molecular process or processes responsible — whether by slow diffusion of siRNA across endosomal limiting membranes, by membrane fusion events (for example fusion of LNP or intraluminal-vesicle membranes with the limiting membrane), by improved access of released siRNA to membrane-associated RISC, or by another process. Separating increased functional cytosolic delivery from mere intracellular retention is part of the question itself: the observable at issue is RISC-mediated silencing, not endosomal accumulation alone.

(2) Determinants of LNP routing: identify the proteins and lipid species governing late-endosome/multivesicular-body biogenesis and the tubulovesicular trafficking and fusion events that route internalized LNPs toward secretion/exocytosis versus degradation versus productive cytosolic delivery.

(3) Generalization and safe exploitation: establish how broadly the NPC1-dependent retention effect and the Rab27b effect hold across LNP chemistries, particle sizes and surface charges in physiologically relevant in-vivo settings, and determine whether transient or targeted inhibition of recycling pathways can improve therapeutic siRNA potency without deleterious effects on cellular lipid homeostasis.

(4) Disease-state implication: determine whether disease states with impaired NPC1 function (lysosomal storage diseases such as Niemann-Pick type C) materially alter in-vivo LNP delivery, and whether that alteration can be exploited therapeutically.

References

  1. Sahay G, Querbes W, Alabi C, Eltoukhy A, Sarkar S, Zurenko C, Karagiannis E, Love K, Chen D, Zoncu R, Buganim Y, Schroeder A, Langer R, Anderson DG. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nature Biotechnology 31, 653-658 (2013). doi:10.1038/nbt.2614, https://doi.org/10.1038/nbt.2614 (free full text: PMC3814166)
  2. Gilleron J, Querbes W, Zeigerer A, Borodovsky A, Marsico G, Schubert U, Manygoats K, Seifert S, Andree C, Stöter M, Epstein-Barash H, Zhang L, Koteliansky V, Fitzgerald K, Fava E, Bickle M, Kalaidzidis Y, Akinc A, Maier M, Zerial M. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nature Biotechnology 31, 638-646 (2013). doi:10.1038/nbt.2612, https://doi.org/10.1038/nbt.2612
  3. Wittrup A, Ai A, Liu X, Hamar P, Trifonova R, Charisse K, Manoharan M, Kirchhausen T, Lieberman J. Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown. Nature Biotechnology 33, 870-876 (2015). doi:10.1038/nbt.3298, https://doi.org/10.1038/nbt.3298
  4. Gibbings DJ, Ciaudo C, Erhardt M, Voinnet O. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nature Cell Biology 11, 1143-1149 (2009). doi:10.1038/ncb1929, https://doi.org/10.1038/ncb1929
  5. Eltoukhy AA, Sahay G, Cunningham JM, Anderson DG. Niemann-Pick C1 affects the gene delivery efficacy of degradable polymeric nanoparticles. ACS Nano 8, 7905-7913 (2014). doi:10.1021/nn501630h, https://doi.org/10.1021/nn501630h
  6. Wang H, Tam YYC, Chen S, Zaifman J, van der Meel R, Ciufolini MA, Cullis PR. The Niemann-Pick C1 inhibitor NP3.47 enhances gene silencing potency of lipid nanoparticles containing siRNA. Molecular Therapy 24, 2100-2108 (2016). doi:10.1038/mt.2016.179, https://doi.org/10.1038/mt.2016.179
  7. Dahiya UR, Ganguli M. Exocytosis - a putative road-block in nanoparticle and nanocomplex mediated gene delivery. Journal of Controlled Release 303, 67-76 (2019). doi:10.1016/j.jconrel.2019.04.012, https://doi.org/10.1016/j.jconrel.2019.04.012
  8. Van de Vyver T, De Smedt SC, Raemdonck K. Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics. Advanced Drug Delivery Reviews 181, 114041 (2022). doi:10.1016/j.addr.2021.114041, https://doi.org/10.1016/j.addr.2021.114041
  9. Van de Vyver T, Muntean C, Efimova I, Krysko DV, De Backer L, De Smedt SC, Raemdonck K. The alpha-adrenergic antagonist prazosin promotes cytosolic siRNA delivery from lysosomal compartments. Journal of Controlled Release 364, 142-158 (2023). doi:10.1016/j.jconrel.2023.10.014, https://doi.org/10.1016/j.jconrel.2023.10.014
  10. Paramasivam P, Franke C, Stöter M, Höijer A, Bartesaghi S, Sabirsh A, Lindfors L, Yanez Arteta M, Dahlén A, Bak A, Andersson S, Kalaidzidis Y, Bickle M, Zerial M. Endosomal escape of delivered mRNA from endosomal recycling tubules visualized at the nanoscale. Journal of Cell Biology 221, e202110137 (2022). doi:10.1083/jcb.202110137, https://doi.org/10.1083/jcb.202110137
  11. Herrera M, Kim J, Eygeris Y, Jozic A, Sahay G. Illuminating endosomal escape of polymorphic lipid nanoparticles that boost mRNA delivery. Biomaterials Science 9, 4289-4300 (2021). doi:10.1039/d0bm01947j, https://doi.org/10.1039/d0bm01947j
  12. Zheng L, Bandara SR, Tan Z, Leal C. Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm. Proceedings of the National Academy of Sciences USA 120, e2301067120 (2023). doi:10.1073/pnas.2301067120, https://doi.org/10.1073/pnas.2301067120
  13. Chatterjee S, Kon E, Sharma P, Peer D. Endosomal escape: A bottleneck for LNP-mediated therapeutics. Proceedings of the National Academy of Sciences USA 121, e2307800120 (2024). doi:10.1073/pnas.2307800120, https://doi.org/10.1073/pnas.2307800120
  14. Pei D. Endosomal escape of lipid nanoparticles: A perspective on the literature data. ACS Nano 19, 40293-40303 (2025). doi:10.1021/acsnano.5c11721, https://doi.org/10.1021/acsnano.5c11721
  15. Omo-Lamai S, Wang Y, Patel MN, Milosavljevic A, Zuschlag D, Poddar S, Wu J, Wang L, Dong F, Espy C, Majumder A, Essien E, Shen M, Channer B, Papp TE, Tobin M, Maheshwari R, Jeong S, Patel S, Shah A, Murali S, Chase LS, Zamora ME, Arral ML, Marcos-Contreras OA, Myerson JW, Hunter CA, Discher D, Gaskill PJ, Tsourkas A, Muzykantov VR, Brodsky I, Shin S, Whitehead KA, Parhiz H, Katzen J, Miner JJ, Trauner D, Brenner JS. Limiting endosomal damage sensing reduces inflammation triggered by lipid nanoparticle endosomal escape. Nature Nanotechnology 20, 1285-1297 (2025). doi:10.1038/s41565-025-01974-5, https://doi.org/10.1038/s41565-025-01974-5
  16. Jozic A, Le Roux C, Kim J, Berchel M, Sahel DK, Bodi EK, Palumbo M, Vasudevan A, Murthy NTV, Eygeris Y, Gautam M, Bloom E, Barnes AP, Jaffrès PA, Sahay G. In vivo endosomal escape assay identifies mechanisms for efficient hepatic LNP delivery. Nature Biotechnology (2026). doi:10.1038/s41587-026-03022-6, https://doi.org/10.1038/s41587-026-03022-6
  17. Liu Z, Dong Y. Quantifying endosomal escape in vivo to guide lipid nanoparticle design. Nature Biotechnology (2026). doi:10.1038/s41587-026-03047-x, https://doi.org/10.1038/s41587-026-03047-x
  18. Luo C, Li Y, Liu H, He J, Yang X, Zhao E, Zi G, Liu L, Hong Y, Wang H, Li T, Yang Z, Wang R, Xu Y, Peng B. Intracellular trafficking of lipid nanoparticles is hindered by cholesterol. International Journal of Pharmaceutics 671, 125240 (2025). doi:10.1016/j.ijpharm.2025.125240, https://doi.org/10.1016/j.ijpharm.2025.125240